Literature DB >> 8890784

Prevalence of multiple sclerosis in Rochdale.

D I Shepherd1, A Summers.   

Abstract

The prevalence of multiple sclerosis in the Rochdale Metropolitan Borough in the north east of Greater Manchester has been established. Case ascertainment was partly prospective via a neurological register from 1979 and by contact with general practitioners, therapists, and social services. On prevalence day, 1 January 1989, 254 patients with multiple sclerosis were living in Rochdale. The overall prevalence was 122/100,000 population and 96/100,000 population for probable cases only. The peak rate for women aged 35 to 44 years was 437/100,000 population and for men aged 45 to 54 years 221/100,000. Familial multiple sclerosis was present in 10.8% of families. In this, the first study in north west England, the prevalence of multiple sclerosis in Rochdale is similar to that in southern England and Wales but lower than that in Scotland.

Entities:  

Mesh:

Year:  1996        PMID: 8890784      PMCID: PMC486587          DOI: 10.1136/jnnp.61.4.415

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

1.  The prevalence of multiple sclerosis in the Southampton and South West Hampshire Health Authority.

Authors:  M H Roberts; J P Martin; D L McLellan; S A McIntosh-Michaelis; A J Spackman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

2.  Mortality rates from multiple sclerosis: geographical and temporal variations revisited.

Authors:  E S Williams; D R Jones; R O McKeran
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-02       Impact factor: 10.154

3.  Epidemiology of multiple sclerosis in London and Middlesex County, Ontario, Canada.

Authors:  W J Hader; M Elliot; G C Ebers
Journal:  Neurology       Date:  1988-04       Impact factor: 9.910

4.  The incidence and mortality of multiple sclerosis in south east Wales.

Authors:  A Hennessy; R J Swingler; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-09       Impact factor: 10.154

5.  The prevalence of multiple sclerosis in south east Wales.

Authors:  R J Swingler; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-12       Impact factor: 10.154

6.  Epidemiology of multiple sclerosis in the north-east (Grampian region) of Scotland--an update.

Authors:  J G Phadke; A W Downie
Journal:  J Epidemiol Community Health       Date:  1987-03       Impact factor: 3.710

7.  Surveying multiple sclerosis in the United Kingdom.

Authors:  N Robertson; A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-01       Impact factor: 10.154

8.  A further prevalence study of multiple sclerosis in north-east Scotland.

Authors:  D I Shepherd; A W Downie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-04       Impact factor: 10.154

9.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

10.  Multiple sclerosis in the Cambridge health district of east Anglia.

Authors:  C J Mumford; M B Fraser; N W Wood; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

View more
  10 in total

1.  The prevalence of multiple sclerosis in the Leeds Health Authority.

Authors:  H L Ford; E Gerry; C M Airey; A Vail; M H Johnson; D R Williams
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

2.  Prevalence of multiple sclerosis in the L'Aquila district, central Italy.

Authors:  R Totaro; C Marini; A Cialfi; M Giunta; A Carolei
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

3.  The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom.

Authors:  Anu Jacob; Jay Panicker; Daniel Lythgoe; Liene Elsone; Kerry Mutch; Martin Wilson; Kumar Das; Mike Boggild
Journal:  J Neurol       Date:  2013-05-21       Impact factor: 4.849

4.  The epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteria.

Authors:  C M Fox; S Bensa; I Bray; J P Zajicek
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-01       Impact factor: 10.154

5.  The p.Ala510Val mutation in the SPG7 (paraplegin) gene is the most common mutation causing adult onset neurogenetic disease in patients of British ancestry.

Authors:  Richard H Roxburgh; Renate Marquis-Nicholson; Fern Ashton; Alice M George; Rod A Lea; David Eccles; Stuart Mossman; Thomas Bird; Koen L van Gassen; Erik-Jan Kamsteeg; Donald R Love
Journal:  J Neurol       Date:  2012-12-27       Impact factor: 4.849

6.  Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity.

Authors:  C McGuigan; A McCarthy; C Quigley; L Bannan; S A Hawkins; M Hutchinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-04       Impact factor: 10.154

7.  Geomagnetic disturbances may be environmental risk factor for multiple sclerosis: an ecological study of 111 locations in 24 countries.

Authors:  Seyed Aidin Sajedi; Fahimeh Abdollahi
Journal:  BMC Neurol       Date:  2012-09-24       Impact factor: 2.474

8.  High incidence and prevalence of multiple sclerosis in south east Scotland: evidence of a genetic predisposition.

Authors:  P M Rothwell; D Charlton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-06       Impact factor: 10.154

9.  Multiple sclerosis in Northern Ireland: a historical and global perspective.

Authors:  G V McDonnell; S A Hawkins
Journal:  Ulster Med J       Date:  2000-11

Review 10.  Incidence and prevalence of multiple sclerosis in Europe: a systematic review.

Authors:  Elaine Kingwell; James J Marriott; Nathalie Jetté; Tamara Pringsheim; Naila Makhani; Sarah A Morrow; John D Fisk; Charity Evans; Sarah Gabrielle Béland; Sophie Kulaga; Jonathan Dykeman; Christina Wolfson; Marcus W Koch; Ruth Ann Marrie
Journal:  BMC Neurol       Date:  2013-09-26       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.